Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
about
Teratogenic mechanisms of medical drugsTargeting the Checkpoint to Kill Cancer CellsHistone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fatGcn5p plays an important role in centromere kinetochore function in budding yeast.A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity.MBD3 and HDAC1, two components of the NuRD complex, are localized at Aurora-A-positive centrosomes in M phaseCyclin A/cdk2 coordinates centrosomal and nuclear mitotic eventsMicronuclei in genotoxicity assessment: from genetics to epigenetics and beyondKaposi sarcoma herpes virus latency associated nuclear antigen protein release the G2/M cell cycle blocks by modulating ATM/ATR mediated checkpoint pathwayTopoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathwayGene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors.Safeguarding entry into mitosis: the antephase checkpoint.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsHistone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cellsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Histone modification enzymes: novel targets for cancer drugs.Histone deacetylase inhibitors equipped with estrogen receptor modulation activity.The SIN3/RPD3 deacetylase complex is essential for G(2) phase cell cycle progression and regulation of SMRTER corepressor levels.Histone deacetylase inhibitors promote osteoblast maturation.The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossThe histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition.RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulationAlp13, an MRG family protein, is a component of fission yeast Clr6 histone deacetylase required for genomic integrity.Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cellsLoss of Sin3/Rpd3 histone deacetylase restores the DNA damage response in checkpoint-deficient strains of Saccharomyces cerevisiae.Histone deacetylase inhibitors in clinical development.Reasons to reconsider the significance of apoptosis for cancer therapy.Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression.Rational Combinations of Targeted Agents in AMLThe ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle blockHistone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defectsTargeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cellsHistone deacetylase inhibitors and malignant melanoma.Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?Histone deacetylase inhibitors: insights into mechanisms of lethality.
P2860
Q22337136-3B966EC8-FCEF-425D-9248-1C39A8AEA58FQ26795781-7B7CA674-761E-4F9A-88A3-FD8A2BDCF3F9Q27324052-7741B425-3423-4947-99A0-E43F13A0CECBQ27937348-3058B58C-AE62-4698-8C5A-362773B6B089Q28115595-F7779B57-A7B1-4D5A-A06F-6A1D09ACED86Q28204554-7762BBD6-3A24-47BD-ACED-9C78B0AD937CQ28274303-2054978A-49FF-4022-840F-227149866080Q28294979-6AF3572E-E720-4CE5-AB39-B70D0BFD309EQ28540116-47C4F5EA-206B-4FD4-B641-E26720FC5C42Q33205671-89E9FF23-3B18-4A12-B071-3D69F0F9376AQ33302058-D8CD1108-6A72-44F3-9A8F-44B84FE8B97DQ33558235-76E464B2-EC00-4628-85C4-75E44C2F82ADQ33761796-AD9F7664-D3C4-4755-A4B4-18D6181AA9C8Q33778532-33CD4E5F-AB67-4389-92D2-43CE7E792903Q33983255-EADD8CA6-4FB2-4590-A144-42487139EF75Q34101029-356FCAD1-51F0-4B59-911D-D22F3E754DD5Q34171631-810F8079-B234-48DE-9F3A-05899221615EQ34322087-4ECC25F4-7A86-42DF-8C45-51F963DBEF65Q34352264-D366E50F-8353-451B-99DF-3AE03EBB732BQ34441108-795A6EE1-64BE-426A-B695-A41C17327487Q34468553-D509FD0C-7820-494B-BFAB-697C0F40DB65Q34686787-96B34F03-C05C-47DF-8A12-0F34B5ECF52FQ34771550-77E251B0-B02C-4F06-B342-7EB688F0B4CEQ34780528-71FA835D-95A8-4914-A2ED-A8A6460F96F2Q34971840-70E7892B-5238-4A6F-9B3D-7194B3E11DF7Q34984418-33A6A178-CC04-4216-9D4B-CAA9C4C31E0BQ35032470-915A2F97-849C-4C1F-A440-4D020B5E3B26Q35070240-6736CF70-FE23-4344-9A2F-1DBBF9CAC539Q35150732-F7996BFA-9151-43A1-A5E5-23BC014F7CA0Q35609717-D17E766A-B342-4173-9E07-809414944BADQ35624645-EA725DCC-9F4B-415E-AD89-B1F6BF69F85DQ35643947-E9720223-63D5-4130-9CEB-6DC0FABC61E7Q35750491-991F809E-0322-4C15-A63C-BE63F9DC8120Q35857290-967777E3-30B4-4C0B-A588-251D57945CBAQ35973630-BF19D6E4-278C-4D3F-82CA-1BDF9AF896D1Q36001852-B28F58A1-8465-4F29-8322-9862175EF3F8Q36126837-17F0EA1D-454A-42FB-9C91-E703217696E0Q36162556-B711A2DB-E8AC-4AC7-AC1C-39E9AB5FAD52Q36179533-ED74F3F5-D0AB-4C98-A953-F4F37A35D537Q36219726-8ADD0D53-45D0-42E2-9E7D-FB62EBB5A289
P2860
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@ast
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@en
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@nl
type
label
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@ast
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@en
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@nl
prefLabel
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@ast
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@en
Histone deacetylase inhibitors ...... t is defective in tumor cells.
@nl
P2093
P2860
P356
P1476
Histone deacetylase inhibitors ...... at is defective in tumor cells
@en
P2093
P2860
P304
P356
10.1091/MBC.11.6.2069
P577
2000-06-01T00:00:00Z